This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Sonoelastography: Ultrasound Method to Measure Liver Fibrosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Anthony Samir, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01747772
First received: October 31, 2012
Last updated: May 12, 2017
Last verified: May 2017
  Purpose

HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) will provide accurate quantitative measurements that can be used to stage liver fibrosis in patients with chronic liver disease.

  1. To measure liver stiffness with sonoelastography in adults with suspect diffuse liver disease who will undergo non-focal liver biopsy as part of their routine clinical care
  2. To assess the sensitivity and specificity of sonoelastography for the detection and staging of liver fibrosis
  3. To evaluate the effect of steatosis and inflammation on the estimation of liver fibrosis using sonoelastography

Condition Intervention
Chronic Liver Disease Non-Alcoholic Fatty Liver Disease Hepatitis C Virus (HCV) Coinfection Hepatitis B Virus (HBV) Drug-Induced Liver Injury Device: Shear Wave Sonoelastography

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Outcomes Assessor
Masking Description:
Biopsy specimens were assessed via Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) criteria by a pathologist who was blinded to the shear-wave elastography (SWE) values.
Primary Purpose: Diagnostic
Official Title: Evaluate the Utility of Shear Wave Sonoelastography as a Tool to Measure Liver Fibrosis Grade

Resource links provided by NLM:


Further study details as provided by Anthony Samir, Massachusetts General Hospital:

Primary Outcome Measures:
  • Liver Elasticity Value Measured Using Sonoelastography (SE) [ Time Frame: Day 1 ]
    Liver elasticity/stiffness was assessed via SE and compared against results of liver biopsy as read by a single pathologist using the Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) 5-point scale (F [Fibrosis]0=no fibrosis, F1=portal fibrosis without septa, F2=portal fibrosis with few septa, F3=numerous septa without cirrhosis, and F4=cirrhosis). Using SE, fibrosis is measured in kilopascals (kPa) with normal values equaling approximately 5.5 kPa (normal liver stiffness ranges between 3.3-7.8 kPa). Significant Fibrosis (F3): = or > 7.6 kPa, Cirrhosis (F4): = or > 9.0- 26 kPa. A higher number corresponds to an increase in stiffness and hepatic fibrosis.


Enrollment: 180
Actual Study Start Date: February 2010
Study Completion Date: February 14, 2014
Primary Completion Date: February 14, 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Shear Wave Sonoelastography for Fibrosis Assessment
Shear Wave sonoelastography (SWE) was performed in patients who were scheduled for a non-focal liver biopsy.
Device: Shear Wave Sonoelastography
Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
Other Name: Supersonic Aixplorer

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients (age 18 or older)
  • Men or women
  • Suspected diffuse liver disease
  • Consent to participate in the study

Exclusion Criteria:

  • Pregnancy
  • Acute illness/cognitive impairment resulting in inability to cooperate with ultrasound.
  • Patients that do not consent to ultrasound or sonoelastography.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01747772

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Anthony E Samir, MD Massachusetts General Hospital
  More Information

Publications:
Responsible Party: Anthony Samir, Associate Director, Ultrasound Imaging Services Assistant Radiologist, Abdominal Imaging & Intervention Massachusetts General Hospital, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01747772     History of Changes
Other Study ID Numbers: 2009P002791
Study First Received: October 31, 2012
Results First Received: March 23, 2017
Last Updated: May 12, 2017

Keywords provided by Anthony Samir, Massachusetts General Hospital:
Non-focal Liver Disease
Fibrosis
Shear Wave Sonoelastography
Metavir Liver Fibrosis Grading

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Fibrosis
Hepatitis B
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Cirrhosis
Drug-Induced Liver Injury
Coinfection
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Pathologic Processes
Hepadnaviridae Infections
DNA Virus Infections
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Poisoning
Infection
Parasitic Diseases
Liver Extracts
Hematinics

ClinicalTrials.gov processed this record on June 23, 2017